ConductScience.org, home

Paper40779124

Nipocalimab: First Approval.

Fung S. Drugs, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Nipocalimab: First Approval. Papers, record 40779124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40779124

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nipocalimab: First Approval.
PubMed
Journal
Drugs
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-05
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fung SSimonhttps://orcid.org/0000-0003-0789-7765

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Myasthenia GravisMajor topic
Antibodies, Monoclonal, HumanizedMajor topic
Humans
Drug Approval
Receptors, Fc
United States
Adult
Child
Histocompatibility Antigens Class I

Source PubMed

Download CSV of topics

References8

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122882218Muscle autoantibodies in myasthenia gravis: beyond diagnosis?Expert Rev Clin Immunol2012https://conductscience.org/library/papers/22882218PubMed
238942592
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.
RMD Open2024https://conductscience.org/library/papers/38942592PubMed
339073504Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers.Clin Drug Investig2024https://conductscience.org/library/papers/39073504PubMed
439115062Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn.N Engl J Med2024https://conductscience.org/library/papers/39115062PubMed
539862879Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.Lancet Neurol2025https://conductscience.org/library/papers/39862879PubMed
630402880M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.Clin Pharmacol Ther2019https://conductscience.org/library/papers/30402880PubMed
738165333Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG StudyNeurology2024https://conductscience.org/library/papers/38165333PubMed
839197469Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn.Am J Perinatol2025https://conductscience.org/library/papers/39197469PubMed

Download CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42921078Polyclonal IgG therapy in neurologic and neuromuscular disease: mechanisms of action and insights from newer therapies.Front Neurol2026https://conductscience.org/library/papers/42921078PubMed
42814271Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis.CNS Drugs2026https://conductscience.org/library/papers/42814271PubMed
42041547Exosomes in Myasthenia Gravis-Review.Cells2026https://conductscience.org/library/papers/42041547PubMed
41807809A year in pharmacology: new drugs approved by the US food and drug administration in 2025.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41807809PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FCGRT2217PubTator's text mininghttps://conductscience.org/library/genes/2217

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40779124

GET https://conductscience.org/api/papers/v1/40779124/authors